Quality & complianceOfficial

Denmark flags Cellcristin vincristine injection supply problems from Orifarm into 2027

🇩🇰 DKMA · Mon 02 Nov 2026

The Danish Medicines Agency lists Orifarm's Cellcristin 1 mg/ml solution for injection as affected by delivery difficulties, with disruption expected to run until the end of March 2027.

The Danish Medicines Agency (DKMA) has published a supply notice on Cellcristin 1 mg/ml solution for injection, marketed in Denmark by Orifarm A/S. The notice is dated 2 November 2026 and refers to current problems with supply.

Cellcristin contains the active substance vincristine, as vincristine sulfate (ATC code L01CA02). DKMA gives the cause as delivery difficulties and does not elaborate on what lies behind them.

The expected period of disruption is listed as the end of February 2026 to the end of March 2027. The notice is dated November 2026, so the start date precedes publication; DKMA does not explain why.

As further information, DKMA says it is possible to apply for a dispensing permission (udleveringstilladelse). Questions about the current status of supply should be put to the company, according to the agency. The notice names no alternative products and gives no clinical guidance.

What it means for your team

  • Supply-chain and market-access teams in Denmark should note the long expected window, to the end of March 2027, when planning stock and contingency arrangements.
  • Regulatory affairs teams can use the route DKMA names, applying for a dispensing permission, as part of any contingency plan. Details of the procedure are not in the notice and should be checked with DKMA.
  • For current availability, contact Orifarm A/S directly, as DKMA directs. Check DKMA's supply notices page for any updates.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →